Published in , the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA) was conducted to. The latest data from ASCOT came from the blood pressure-lowering arm of the trial (ASCOT-BPLA). Following the presentation of preliminary. Cardiac Outcomes Trial: Blood Pressure-Lowering Arm – ASCOT-BPLA The ASCOT trial revealed the benefit of amlodipine/perindopril for.
|Published (Last):||2 November 2010|
|PDF File Size:||6.96 Mb|
|ePub File Size:||18.88 Mb|
|Price:||Free* [*Free Regsitration Required]|
On the basis of previous trial evidence, these effects might not be entirely explained by better control of blood pressure, and this issue is addressed in the accompanying article. Navigation menu Personal tools Teial account Log in.
Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril. Though not significant, compared with the atenolol-based regimen, fewer individuals on the amlodipine-based regimen had a primary endpoint vs ; unadjusted HR 0.
Our primary endpoint was non-fatal myocardial infarction including silent myocardial infarction and fatal CHD. The amlodipine-based regimen prevented awcot-bpla major cardiovascular events and induced less diabetes than the atenolol-based regimen. The amlodipine-based arm had a significantly lower blood pressure than the atenolol-based arm throughout the entire study that may explain the differences in outcomes.
Nevertheless, the results have implications with respect to optimum combinations of antihypertensive agents. The apparent shortfall in prevention of coronary heart disease CHD noted in early hypertension trials has been attributed tral disadvantages of the diuretics and beta blockers used. Republished in Curr Hypertens Rep.
The study was stopped prematurely after 5. Views Read View source View history.
ASCOT-BPLA – Wiki Journal Club
We did a multicentre, prospective, randomised controlled trial in 19 patients with hypertension who were aged years and had at least three other cardiovascular risk factors.
Retrieved from ” http: The trial was stopped prematurely due to a large difference in all-cause mortality between the two treatment groups.
Among hypertensive patients at high risk of cardiovascular disease, does a combination regimen of amlodipine ascot-bpka perindopril prevent more cardiovascular events than atenolol and bendroflumethiazide?
The main objective of hypertension treatment is to attain and maintain goal BP.
The clinician should continue to assess BP and adjust the treatment regimen until goal BP is reached. At the time, calcium channel blockers CCBs and ACE inhibitors ACEIs were novel antihypertensive agents hypothesized to have less adverse metabolic effects and provide additional cardiovascular protection beyond its blood pressure effects.
For a given reduction in blood pressure, some suggested that newer agents would confer advantages over diuretics and beta blockers. If goal BP cannot be reached with 2 drugs, add and titrate a third drug from the list provided.
It was hypothesized that adverse side effects of older antihypertensive agents, such as beta-blockers and diuretics, was partially offsetting the benefit of blood pressure reduction .
Analysis was by intention to treat. Secondary outcomes suggest a possible reduction in cardiovascular morbidity and mortality using amlodipine and perindopril, although this may be ascribed to differences in blood pressure between the two study arms.
Amlodipine and perindopril does not reduce cardiovascular morbidity and mortality compared to atenolol and bendroflumethiazide. The incidence of developing diabetes was less on the amlodipine-based regimen vs ; 0. Expert Opinion — Grade E. However, the size of benefit was significantly less than predicted compared to previous observational studies . Intensive blood pressure lowering regimens had been shown in multiple randomized control trials to reduce cardiovascular moribidity and mortality.
This page was last modified on 15 Septemberat However, the trial was underpowered as it was stopped early due to a significant reduction in all cause-mortality in the amlodipine and perindopril arm.
The lack of statistical significance may have been due to early trial termination, as the trial did not meet the pre-specified number of primary events of